Skip to main content
Log in

Antibiotic pharmacodynamics and bacterial resistance: Usefulness of in vitro models

  • Invited Commentary
  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Firsov AA, Chernykh VM, Navashin SM: Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model. Antimicrob Agents Chemother 1990, 34:1312–1317.

    PubMed  CAS  Google Scholar 

  2. Firsov AA, Lubenko IY, Vostrov SN, et al.: Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones. Antimicrob Agents Chemother 2005, 49:2642–2647.

    Article  PubMed  CAS  Google Scholar 

  3. Forrest A, Chodosh S, Amantea MA, et al.: Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997, 40(Suppl A):45–57.

    Article  PubMed  CAS  Google Scholar 

  4. Preston SL, Drusano GL, Berman AL, et al.: Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother 1998, 42:1098–1104.

    PubMed  CAS  Google Scholar 

  5. Firsov AA, Vostrov SN, Lubenko IY, et al.: In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003, 47:1604–1613.

    Article  PubMed  CAS  Google Scholar 

  6. Zhao X, Drlica K: Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001, 33:147–156.

    Article  Google Scholar 

  7. Zinner SH, Lubenko IY, Gilbert D, et al.: Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother 2003, 52:616–622.

    Article  PubMed  CAS  Google Scholar 

  8. Firsov AA, Smirnova MV, Lubenko IY, et al.: Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother 2006, 58:1185–1192.

    Article  PubMed  CAS  Google Scholar 

  9. Tam VH, Louie A, Deziel MR, et al.: Bacterial-population responses to drug-selective pressure: examination of garenoxacin’s effect on Pseudomonas aeruginosa. J Infect Dis 2005, 192:420–428.

    Article  PubMed  Google Scholar 

  10. Campion JJ, McNamara PJ, Evans ME: Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments. Antimicrob Agents Chemother 2004, 48:4733–4744.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stephen H. Zinner MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zinner, S.H., Firsov, A. Antibiotic pharmacodynamics and bacterial resistance: Usefulness of in vitro models. Curr Infect Dis Rep 9, 175–177 (2007). https://doi.org/10.1007/s11908-007-0027-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-007-0027-y

Keywords

Navigation